Funding
← Back to your selection

Atypical Ventures

Activity from announced rounds

Activity in this selectionUnited States

Atypical Ventures is Christopher Wake’s investment firm, associated with frontier-technology investing.

Recorded funding activity

Its recorded financings include Shennon Biotechnologies’ precision T-cell engagers for solid tumors, PhoenixAI’s analytical database for agents querying enterprise data, and Ventaris Surgical’s ureteroscopic system for kidney-stone clearance. The companies’ own announcements identify Atypical Ventures across these different technologies.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$122M
3 disclosed · full round size, not this investor’s share

By stage

Series A1
Series B1
Undisclosed1

By primary sector

AI1
Biotech1
Healthtech1

By country

United States3

Rounds

3 in this selection
Shennon Biotechnologies

Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.

$12MFunding
Participant
PhoenixAI

AI-native analytical database enabling AI agents to query live and historical enterprise data at sub-second latency

$80MSeries B
Role not disclosed
Ventaris Surgical

Develops a ureteroscopic system for complete kidney stone clearance

$30MSeries A
Role not disclosed